Search
for

    Sort by

    Community Join

    120-150 / 1000+ results

      community Kintor pyrilutamide presentation?

      in Research/Science  12 upvotes 2 years ago
      The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

      community Second shed, non-stop flaking, itching

      in Treatment  12 upvotes 7 months ago
      The user is experiencing a second hair shedding phase and increased flaking and itching while using minoxidil 5% nightly and microneedling every two weeks, with needle length increasing over time. Other users suggest the hair loss may continue without the use of finasteride.

      community Chances of GT20029 hitting the black market?

      in Treatment  11 upvotes 8 months ago
      The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.

      community Where is GT20029 already? Grrrr

      in Research/Science  19 upvotes 10 months ago
      The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

      community Second Shed recovery Motivation

      in Progress Pictures  150 upvotes 8 months ago
      A user shared their experience with hair recovery after a second shedding phase while using Finasteride. They advise staying consistent with treatment, as it can take 1-2 years or more to see results, and also mention using Ketoconazole but are unsure of its effectiveness.

      community Is there any new drug that looks promising ?

      in Research/Science  25 upvotes 9 months ago
      The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

      community Surprisingly thorough study on He-Shou-Wu/Fo Ti

      in Research/Science  14 upvotes 1 year ago
      He Shou Wu (Fo Ti) extract was found to prolong the hair growth phase, inhibit 5-alpha-reductase (like finasteride), reduce androgen receptors, and increase growth factors, potentially outperforming minoxidil in recovering hair follicle size after DHT exposure. Two compounds, emodin and TSG, are identified as responsible for these effects and warrant further investigation.

      community Any updates or news on Gt20029?

      in Chat  9 upvotes 1 month ago
      There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

      community Why I still have faith in KX-826

      in Research/Science  54 upvotes 4 months ago
      KX-826 shows promise for hair maintenance at higher doses with minimal side effects, despite failing Phase III trials. The user believes it is more effective than Minoxidil, Finasteride, and RU58841.

      community Is Anyone using Latanoprost at all?

      in Product  9 upvotes 8 months ago
      A user discusses using latanoprost, a costly treatment that may extend the hair growth phase and improve hair quality, wondering why it's not more popular. They already use a combination of finasteride and minoxidil and plan to incorporate latanoprost into their routine.

      community Second shed and what I have learned (don't worry!)

      in Minoxidil  45 upvotes 10 months ago
      A 25-year-old experienced significant hair regrowth using 5% minoxidil for 9.5 months despite an initial shed and a second shedding phase lasting 3.5 months. They encourage others to persist with minoxidil treatment through shedding as regrowth can occur.

      community Hope Medicine HMI-115 got 28M$ investment

      in Research/Science  59 upvotes 10 months ago
      Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.

      community Any updates on RCH-01?

      in Question  12 upvotes 5 years ago
      The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.

      community Almost 3 years of dht blockers and my ups and downs

      in Is this regrowth?  74 upvotes 1 week ago
      The user experienced hair loss starting at 16 and used finasteride and minoxidil, later switching to dutasteride and oral minoxidil, which improved hair thickness after an initial shedding phase. The user also noted the importance of using shampoo to manage dermatitis and maintain scalp health.

      community Progress update just over a year in

      in Progress Pictures  143 upvotes 1 month ago
      The user has been using 2mg minoxidil and 1mg finasteride daily for over a year, with inconsistent use for two months, and is experiencing a shedding phase. Suggestions include adding dutasteride, micro-needling, and considering a shorter haircut to manage appearance during shedding.

      community Tretinoin every other day? (with daily minoxidil)

      in Minoxidil  1 upvotes 2 months ago
      The user is considering using Tretinoin every other day alongside daily Minoxidil to manage hair loss and is concerned about inconsistent absorption affecting regrowth. They have noticed a significant reduction in shedding but are unsure if it's due to Tretinoin or the end of the Minoxidil/finasteride shedding phase.

      community The story of RU58841/PSK3841

      in Research/Science 4 months ago
      RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.